The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial.
Robert John Motzer
No relevant relationships to disclose
Thomas E. Hutson
No relevant relationships to disclose
Mark R. Olsen
No relevant relationships to disclose
Gary R. Hudes
No relevant relationships to disclose
John M. Burke
No relevant relationships to disclose
William Jeffery Edenfield
No relevant relationships to disclose
George Wilding
No relevant relationships to disclose
Bridget Martell
No relevant relationships to disclose
Subramanian Hariharan
No relevant relationships to disclose
Robert A. Figlin
No relevant relationships to disclose